ArticleScientific reports2025
Incidence rate of Rift Valley fever exposure in humans and livestock from a longitudinal study in Northern Kenya.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Seroincidence of Brucella spp. infection among humans and livestock in a pastoralist setting in Northern Kenya.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unravelling the mechanisms of Rift Valley fever virus (RVFV) maintenance in endemic areas during interepidemic periods is critical for enhancing early detection and response. Unfortunately, data on key epidemiological parameters, such as incidence rates, which are crucial for risk assessments and designing targeted interventions, are almost nonexistent. We conducted a longitudinal study of 1,938 pastoral livestock and 814 livestock keepers in an endemic region of northern Kenya from March 2022 to May 2023 to estimate the incidence rate of RVFV exposure and determine risk factors for infection. We assessed exposure to RVFV in humans and livestock using an anti-RVF immunoglobulin enzyme-linked immunosorbent assay. RVFV incidence was calculated in livestock and humans as the number of new seroconversions over the total animal and person time at risk, respectively. An interval-censored regression model was employed to compute the baseline hazard and identify risk factors. We observed 113 new livestock infections over 805 animal-years at risk, translating to an annual livestock incidence rate of 0.14 per animal-year (95% CI: 0.12-0.17). Multivariable analysis found species, acaricide use, and period of sampling were significant factors that influence RVFV incidence in livestock. In humans, 15 RVFV seroconversions were observed over 629 person-years at risk, yielding an incidence rate of 24 per 1000 person-years (95% CI: 13-39). Age and sex were not significant predictors of RVFV human exposure. Seroconversion in livestock and humans suggests that low-level transmission between vertebrate hosts and vectors could be the primary mechanism for RVF viral persistence in endemic areas. Our findings highlight the need for routine serosurveillance and continuous public health education on RVF infection and prevention during interepidemic periods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.